Cargando…
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
Prediction of human pharmacokinetics (PK) based on preclinical information for antibody–drug conjugates (ADCs) provide important insight into first‐in‐human (FIH) study design. This retrospective analysis was conducted to identify an appropriate scaling method to predict human PK for ADCs from anima...
Autores principales: | Li, Chunze, Zhang, Cindy, Deng, Rong, Leipold, Douglas, Li, Dongwei, Latifi, Brandon, Gao, Yuying, Zhang, Crystal, Li, Zao, Miles, Dale, Chen, Shang‐Chiung, Samineni, Divya, Wang, Bei, Agarwal, Priya, Lu, Dan, Prabhu, Saileta, Girish, Sandhya, Kamath, Amrita V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742937/ https://www.ncbi.nlm.nih.gov/pubmed/31115997 http://dx.doi.org/10.1111/cts.12649 |
Ejemplares similares
-
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
por: Li, Chunze, et al.
Publicado: (2019) -
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
por: Leipold, Douglas, et al.
Publicado: (2018) -
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020) -
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021) -
Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)